RxDoctor Payments Data

Mark Glanzer, OD

Optometrist · Mt Pleasant, TXNPI 1336121003

Payments from drug & device makers

$2,087in general payments, 2019–2025

Across 87 payments — averaging $23.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$280
  • Bausch & Lomb Americas Inc.$273
  • Notal Vision, Inc.$268
  • Biotissue Holdings Inc.$233
  • Sun Pharmaceutical Industries Inc.$204
  • AbbVie$188
  • plus $642 from 10 others

What the payments were for

  • Speaking & faculty fees$26813%
  • Food & beverage$1,81987%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,087 in reported general payments places this provider in the 70th percentile of 4,315 optometrist providers in Texas.

See all optometrist providers in Texas

Medicare billing

Part B allowed, 2024
$503,110
Medicare patients
1,662
Services billed
6,640

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine361$427,081
XiidraLifitegrast140$186,617
Cyclosporine134$74,822
LumiganBimatoprost106$40,323
ProlensaBromfenac Sodium94$32,579
CombiganBrimonidine Tartrate/Timolol74$21,946
VyzultaLatanoprostene Bunod41$14,505
Prednisolone Acetate419$13,812
TyrvayaVarenicline Tartrate21$12,356
Ketorolac Tromethamine619$11,301
EysuvisLoteprednol Etabonate15$8,515
Tobramycin-DexamethasoneTobramycin/Dexamethasone189$8,088
Bromfenac Sodium36$7,268
Latanoprost730$6,101
Travoprost24$5,685

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$188$492,133555 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$273$201,122181 claims
Oyster Point Pharma, Inc.Tyrvaya$155$12,35621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,315 optometrist providers in Texas.

Other optometrist in Mt Pleasant

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →